Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFH375 in KRAS G12D mutant advanced solid tumors
NCT06500676Phase 2Recruiting
- Sponsor
- GenFleet Therapeutics
- Start
- Jul 2024
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GFH375 in solid tumor (advanced stage), sponsored by GenFleet Therapeutics. Primary endpoints: Adverse Events at 24 months, Dose-Limiting Toxicity at 21 days and 1 more. Started Jul 2024; status: recruiting.
02
Drugs
GFH375
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06500676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06500676.